YMAB vs. PAHC, SDGR, AUPH, AVDL, JANX, EVO, RCUS, STOK, LENZ, and SNDX
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Phibro Animal Health (PAHC), Schrodinger (SDGR), Aurinia Pharmaceuticals (AUPH), Avadel Pharmaceuticals (AVDL), Janux Therapeutics (JANX), Evotec (EVO), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.
Y-mAbs Therapeutics vs. Its Competitors
Y-mAbs Therapeutics (NASDAQ:YMAB) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Y-mAbs Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
70.9% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 19.7% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Phibro Animal Health has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Phibro Animal Health had 19 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 20 mentions for Phibro Animal Health and 1 mentions for Y-mAbs Therapeutics. Phibro Animal Health's average media sentiment score of 0.64 beat Y-mAbs Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.
Phibro Animal Health has a net margin of 3.73% compared to Y-mAbs Therapeutics' net margin of -26.03%. Phibro Animal Health's return on equity of 32.14% beat Y-mAbs Therapeutics' return on equity.
Y-mAbs Therapeutics presently has a consensus price target of $9.62, indicating a potential upside of 11.76%. Phibro Animal Health has a consensus price target of $28.40, indicating a potential downside of 22.36%. Given Y-mAbs Therapeutics' higher probable upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than Phibro Animal Health.
Summary
Phibro Animal Health beats Y-mAbs Therapeutics on 15 of the 17 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:YMAB) was last updated on 10/14/2025 by MarketBeat.com Staff